Table 2

Patient demographics and characteristics

CharacteristicETN+MTX (n=276)MTX (n=218)
Low MTX doseMedium MTX doseHigh MTX doseLow MTX doseMedium MTX doseHigh MTX dose
n=73n=155n=48n=39n=117n=62
Age, years51.1 (12.65)51.7 (12.74)51.7 (14.32)56.1 (12.72)50.7 (12.11)51.8 (13.18)
Female, n (%)55 (75)117 (75)33 (69)31 (79)94 (80)50 (81)
Weight, kg69.6 (15.53)70.2 (13.37)75.0 (17.70)67.6 (11.95)71.1 (16.26)70.4 (15.52)
Disease duration, years5.5 (5.55)5.1 (5.13)0.8 (1.48)8.3 (6.05)4.7 (4.91)0.8 (1.10)
Patient Global Assessment6.8 (2.15)7.1 (1.73)7.2 (1.82)6.8 (1.60)6.7 (1.83)6.4 (1.89)
DAS286.4 (1.05)6.8 (1.04)6.8 (0.99)6.5 (0.88)6.7 (0.99)6.3 (0.96)
HAQ-DI1.6 (0.67)1.8 (0.60)2.0 (0.57)1.6 (0.60)1.7 (0.68)1.7 (0.63)
EQ-5D VAS45.8 (24.85)40.9 (21.10)40.5 (22.77)41.8 (20.09)38.6 (21.32)48.8 (21.94)
  • Data represent mean values (SD), unless otherwise specified.

  • DAS28, Disease Activity Score in 28 joints; EQ-5D VAS, EuroQol 5-dimensions visual analogue scale; ETN, etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate.